Neonatal Abstinence Score
To assess the signs/severity of withdrawal in an infant
The Neonatal Abstinence Score is a standardized tool (most commonly the Finnegan system) that quantifies withdrawal severity in opioid‑exposed newborns to guide treatment initiation and monitoring 1 [Level III evidence].
Indications for Use
Used to assess opioid‑exposed neonates with suspected withdrawal to determine severity, need for pharmacologic therapy, and response to treatment. Standard tools (e.g., Finnegan) predict treatment necessity (simplified version validated against full tool in 424 infants 1 [Level II evidence]). Guides timing/escalation of opioids and supports decisions on non‑pharmacologic care; alternative function‑based approaches (Eat‑Sleep‑Console) reduce treatment and length of stay in RCTs 2 [Level I evidence].
Insights & Cautions
Scores guide withdrawal treatment but remain subjective with limited psychometric reliability and high inter‑rater variability 1. High scores can occur in non–opioid conditions, vary with gestational age, and overestimate severity in preterm infants 2. Simplified versions correlate with full scales but still lack robust validation 3. Frequent scoring may trigger unnecessary pharmacologic therapy. Transitioning to functional assessment models (eat, sleep, console) reduces overtreatment without compromising safety 4.